Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

This Phase I/II study tests a new chemotherapy combination (irinotecan plus POF — paclitaxel, oxaliplatin, and 5-FU) in patients with advanced biliary tract cancer (cancers of the bile ducts or gallbladder) that has stopped responding to standard treatment. **You may be eligible if...** - You have advanced biliary tract cancer (bile duct or gallbladder cancer) - Your cancer has progressed on at least one prior line of chemotherapy - You are 18 or older - You are in reasonably good physical condition (ECOG 0-2) - Your organ function is adequate **You may NOT be eligible if...** - You have severe nerve damage (neuropathy) from prior chemotherapy - You have active brain metastases - You are pregnant or breastfeeding - You have had a prior bone marrow transplant Talk to your doctor to see if this trial is right for you.